Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2024 08:05 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
May 23, 2024 07:10 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024
May 16, 2024 07:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 13, 2024 07:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024
March 19, 2024 07:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial...
February 27, 2024 07:30 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve...
February 01, 2024 08:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve...
January 29, 2024 16:01 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
January 25, 2024 07:00 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
January 24, 2024 16:05 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...